The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.
Risk for cancer, mortality increased for patients with pediatric-onset ulcerative colitis, Crohn disease.
Low-, zero-calorie sweetened beverage consumers take in 200 extra calories daily vs water drinkers.
Children of mothers with the highest level of nut intake have better scores on cognitive tests.
Infants with X-linked severe combined immunodeficiency were found to have fully functioning immune systems following treatment with gene therapy.
Recent data suggest that FS may contribute to sudden unexplained death in childhood.
Ruzurgi previously approved for treatment in adults with Lambert-Eaton myasthenic syndrome.
Investigator data shows a higher risk for suicide in patients with schizophrenia who have experienced childhood trauma with an increase in suicidal ideation linked to neglect and depression, while suicide attempts were associated with sexual abuse.
Periodontal disease, caries, or both tied to subclinical atherosclerosis in adulthood.
Strongest correlation seen at ages 0 to 9 years; risk still increased at 10 to 19, 20 to 43 years.
Children and adolescents undergoing infusion therapy for migraine were found to have higher levels of functional disability and a lower quality of life compared with patients not receiving infusion therapy.
Prevention programs may improve long-term outcomes in children and adolescents by addressing pre-existing vulnerabilities that increase the risk for exposure to bullying.
The International Headache Society through roundtable discussion with stakeholders, such as the Clinical Trials and the Child and Adolescent Standing Committees, including lay people and pharmaceutical professionals, updated their guidelines for controlled trials of preventive treatment for migraines within the pediatric population.
The Food and Drug Administration (FDA) has approved the intravenous (IV) formulation of Benlysta (belimumab; GlaxoSmithKline) for the treatment of pediatric patients ≥5 years old with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
Ratio of prematurity, small for gestational age higher in newborns with disorders of sex development.
WHO guidelines similar to recommendations from the American Academy of Pediatrics.
Significant increases seen in rates for whites, Asian/Pacific Islanders, blacks; in Midwest and Northeast.
Most children reached maintenance; 0.4% had severe adverse reaction.
Women whose HbA1c levels were consistent with target values also at increased risk for preterm birth.
Almost 20% of refugee children have elevated blood lead levels.